Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer

Journal of Infection

Volumn 66, Issue 3, 2013, Pages 207-217

  Chelimo, Carol ^a   Wouldes, Trecia A ^b   Cameron, Linda D ^c   Elwood, J Mark ^a  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cervix cancer; Papillomavirus infections; Prevention; Risk factors; Warts

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ACQUISITION OF NEW MALE PARTNER; ADENOCARCINOMA; CANCER IMMUNIZATION; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHLAMYDIASIS; CIRCUMCISION; CONDOM; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; DRUG EFFICACY; ETHNICITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION PREVENTION; INFECTION RISK; MEDICAL HISTORY; NON MONOGAMOUS MALE PARTNER; NONHUMAN; NUMBER OF LIFETIME SEXUAL PARTNER; ORAL CONTRACEPTION; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; REVIEW; RISK FACTOR; SAFE SEX; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SMOKING; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL INTRAEPITHELIAL NEOPLASIA; VIRUS LOAD;

CONDYLOMATA ACUMINATA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84873268454     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.10.024     Document Type: Review

References (109)

1. Baker T.S., Newcomb W.W., Olson N.H., Cowsert L.M., Olson C., Brown J.C. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 1991, 60(6):1445-1456.
2. Favre M. Structural polypeptides of rabbit, bovine, and human papillomaviruses. J Virol 1975, 15(5):1239-1247.
3. IARC monographs on the evaluation of carcinogenic risks to human. Human papillomaviruses 2007, vol. 90. International Agency for Research on Cancer, Lyon (France).
4. Muñoz N., Castellsagué X., de González A.B., Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24(Suppl. 3):S1-S10. 10.1016/j.vaccine.2006.05.115.
5. Stanley M. Immune responses to human papillomavirus. Vaccine 2006, 24(Suppl. 1):S16-S22.
6. Castellsagué X., de Sanjosé S., Aguado T., Louie K.S., Bruni L., Muñoz J., et al. HPV and cervical cancer in the world. 2007 report. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Vaccine 2007, 25(Suppl. 3):C1-C230.
7. Clifford G.M., Gallus S., Herrero R., Muñoz N., Snijders P.J.F., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366(9490):991-998.
8. de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7(7):453-459.
9. Burk R.D., Ho G.Y.F., Beardsley L., Lempa M., Peters M., Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996, 174(4):679-689.
10. IARC monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses 1995, International Agency for Research on Cancer, Lyon (France).
11. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527. 10.1056/NEJMoa021641.
12. Jacobs M.V., de Roda Husman A.M., van den Brule A.J., Snijders P.J., Meijer C.J., Walboomers J.M. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 1995, 33(4):901-905.
13. Bulkmans N.W.J., Berkhof J., Bulk S., Bleeker M.C.G., van Kemenade F.J., Rozendaal L., et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007, 96(9):1419-1424.
14. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995, 87(11):796-802. 10.1093/jnci/87.11.796.
15. Clifford G.M., Smith J.S., Plummer M., Muñoz N., Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88(1):63-73.
16. zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 1977, 78:1-30.
17. Boshart M., Gissmann L., Ikenberg H., Kleinheinz A., Scheurlen W., zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984, 3(5):1151-1157.
18. Durst M., Gissmann L., Ikenberg H., zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 1983, 80(12):3812-3815.
19. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
20. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632. 10.1002/ijc.22527.
21. Winer R.L., Kiviat N.B., Hughes J.P., Adam D.E., Lee S.-K., Kuypers J.M., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005, 191(5):731-738. 10.1086/427557.
22. Bosch F.X., de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007, 23(4):213-227.
23. Smith J.S., Bosetti C., Muñoz N., Herrero R., Bosch F.X., Eluf-Neto J., et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004, 111(3):431-439.
24. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14(2):467-475. 10.1158/1055-9965.epi-04-0551.
25. Leiter U., Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer - the role of sunlight. Adv Exp Med Biol 2008, 624:89-103. 10.1007/978-0-387-77574-6_8.
26. National Cancer Institute Skin cancer 2011, [homepage of the internet], National Cancer Institute at the National Institute of Health, Bethesda, MD (USA), [cited 2011 June 27]. Available from:. http://www.cancer.gov/cancertopics/types/skin.
27. Pfister H. Chapter 8: human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003, 2003(31):52-56.
28. Kjaer S.K., Chackerian B., van den Brule A.J.C., Svare E.I., Paull G., Walbomers J.M.M., et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001, 10(2):101-106.
29. Winer R.L., Lee S.-K., Hughes J.P., Adam D.E., Kiviat N.B., Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157(3):218-226. 10.1093/aje/kwf180.
30. Brown D.R., Shew M.L., Qadadri B., Neptune N., Vargas M., Tu W., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005, 191(2):182-192.
31. Karlsson R.P., Jonsson M., Edlund K., Evander M.P., Gustavsson A.P., Boden E.P., et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex Transm Dis 1995, 22(2):119-127.
32. Ley C., Bauer H.M., Reingold A., Schiffman M.H., Chambers J.C., Tashiro C.J., et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991, 83(14):997-1003. 10.1093/jnci/83.14.997.
33. Kjaer S.K., van den Brule A.J., Bock J.E., Poll P.A., Engholm G., Sherman M.E., et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types?. Cancer Epidemiol Biomarkers Prev 1997, 6(10):799-805.
34. Vaccarella S., Franceschi S., Herrero R., Muñoz N., Snijders P.J.F., Clifford G.M., et al. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006, 15(2):326-333. 10.1158/1055-9965.epi-05-0577.
35. Bosch F.X., Castellsagué X., Muñoz N., de Sanjosé S., Ghaffari A.M., Gonzalez L.C., et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996, 88(15):1060-1067. 10.1093/jnci/88.15.1060.
36. Muñoz N., Castellsagué X., Bosch F.X., Tafur L., de Sanjosé S., Aristizabal N., et al. Difficulty in elucidating the male role in cervical cancer in Colombia, a high-risk area for the disease. J Natl Cancer Inst 1996, 88(15):1068-1075. 10.1093/jnci/88.15.1068.
37. Gissmann L., Wolnik L., Ikenberg H., Koldovsky U., Schnürch H.G., zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A 1983, 80(2):560-563.
38. Greer C.E., Wheeler C.M., Ladner M.B., Beutner K., Coyne M.Y., Liang H., et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995, 33(8):2058-2063.
39. Brown D.R., Schroeder J.M., Bryan J.T., Stoler M.H., Fife K.H. Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999, 37(10):3316-3322.
40. Wiley D.J., Douglas J., Beutner K., Cox T., Fife K., Moscicki A.-B., et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002, 35(Suppl. 2):S210-S224. 10.1086/342109.
41. Lacey C.J.N. Therapy for genital human papillomavirus-related disease. J Clin Virol 2005, 32(Suppl. 1):S82-S90.
42. Insinga R.P., Dasbach E.J., Elbasha E.H. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005, 23(11):1107-1122.
43. Insinga R.P., Dasbach E.J., Myers E.R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003, 36(11):1397-1403. 10.1086/375074.
44. Langley P.C., White D.J., Drake S.M. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004, 15(8):501-508. 10.1258/0956462041558168.
45. Lacey C.J.N., Lowndes C.M., Shah K.V. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006, 24(Suppl. 3):S35-S41.
46. Maw R.D., Reitano M., Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998, 9(10):571-578. 10.1258/0956462981921143.
47. Monteiro E.F., Lacey C.J.N., Merrick D. The interrelation of demographic and geospatial risk factors between four common sexually transmitted diseases. Sex Transm Infect 2005, 81(1):41-46. 10.1136/sti.2004.009431.
48. Kjaer S.K., Trung Nam T., Sparen P., Tryggvadottir L., Munk C., Dasbach E., et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007, 196(10):1447-1454. 10.1086/522863.
49. Fenton K.A., Korovessis C., Johnson A.M., McCadden A., McManus S., Wellings K., et al. Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection. Lancet 2001, 358(9296):1851-1854.
50. Grulich A.E., de Visser R.O., Smith A.M.A., Risse C.E., Richters J. Sex in Australia: sexually transmissible infection and blood-borne virus history in a representative sample of adults. Aust N Z J Public Health 2003, 27(2):234-241. 10.1111/j.1467-842X.2003.tb00814.x.
51. Dinh T.-H., Sternberg M., Dunne E.F., Markowitz L.E. Genital warts among 18- to 59-year-olds in the United States, National Health and Nutrition Examination Survey, 1999-2004. Sex Transm Dis 2008, 35(4):357-360.
52. Garland S.M., Steben M., Sings H.L., James M., Lu S., Railkar R., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (Types 6, 11, 16, and 18) Vaccine. J Infect Dis 2009, 199(6):805-814. 10.1086/597071.
53. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370(9590):890-907.
54. International Agency for Research on Cancer.GLOBOCAN 2008 Cervical cancer incidence and mortality worldwide in 2008 2008, [homepage of the internet], IARC, Lyon (France), [cited 2011 June 28]. Available from:. http://globocan.iarc.fr/factsheets/cancers/cervix.asp.
55. Buckley J.D., Doll R., Harris R.W.C., Vessey M.P., Williams P.T. Case-control study of the husbands of women with dysplasia or carcinoma of the cervix uteri. Lancet 1981, 318(8254):1010-1015.
56. Pridan H., Lilienfeld A.M. Carcinoma of the cervix in Jewish women in Israel, 1960-67: an epidemiological study. Isr J Med Sci 1971, 7:1465-1470.
57. Brinton L.A., Hamman R.F., Huggins G.R., Lehman H.F., Levine R.S., Mallin K., et al. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst 1987, 79(1):23-30.
58. Smith J.S., Green J., de Gonzalez A.B., Appleby P., Peto J., Plummer M., et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003, 361(9364):1159-1167.
59. Smith J., Herrero R., Erles K., Grimm D., Muñoz N., Bosch F.X., et al. Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia. Int J Cancer 2001, 94(4):520-526. 10.1002/ijc.1496.
60. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006, 119(5):1108-1124. International Collaboration of Epidemiological Studies of Cervical Cancer.
61. Muñoz N., Franceschi S., Bosetti C., Moreno V., Herrero R., Smith J.S., et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002, 359(9312):1093-1101.
62. Castle P.E., Wacholder S., Lorincz A.T., Scott D.R., Sherman M.E., Glass A.G., et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002, 94(18):1406-1414. 10.1093/jnci/94.18.1406.
63. Giuliano A.R., Sedjo R.L., Roe D.J., Harris R., Baldwin S., Papenfuss M.R., et al. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002, 13(9):839-846. 10.1023/a:1020668232219.
64. Cogliano V., Grosse Y., Baan R., Straif K., Secretan B., El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005, 6(8):552-553. 10.1016/s1470-2045(05)70273-4.
65. IARC monographs on the evaluation of carcinogenic risks to human. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy 2007, vol. 91. International Agency for Research on Cancer, Lyon (France).
66. Moreno V., Bosch F.X., Muñoz N., Meijer C.J.L.M., Shah K.V., Walboomers J.M.M., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002, 359(9312):1085-1092.
67. Smith J.S., Herrero R., Bosetti C., Muñoz N., Bosch F.X., Eluf-Neto J., et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002, 94(21):1604-1613. 10.1093/jnci/94.21.1604.
68. García-Closas R., Castellsagué X., Bosch X., González C.A. The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence. Int J Cancer 2005, 117(4):629-637.
69. Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G., et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007, 57:7-28.
70. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943. 10.1056/NEJMoa061760.
71. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007, 369(9574):1693-1702.
72. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927. The FUTURE II Study Group. 10.1056/NEJMoa061741.
73. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493. The FUTURE I/II Study Group. 10.1136/bmj.c3493.
74. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347(21):1645-1651. 10.1056/NEJMoa020586.
75. Ault K.A., Giuliano A.R., Edwards R.P., Tamms G., Kim L.-L., Smith J.F., et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004, 22(23-24):3004-3007.
76. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6(5):271-278. 10.1016/s1470-2045(05)70101-7.
77. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.-B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367(9518):1247-1255.
78. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369(9580):2161-2170.
79. U.S.Food and Drug Administration FDA approves new vaccine for prevention of cervical cancer 2009, [homepage on the internet], U.S. FDA, Silver Spring, MD (USA), [updated 16 February, 2010; cited 2011 June 27]. Available from:. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm187048.htm.
80. Wright T.C., Bosch F.X., Franco E.L., Cuzick J., Schiller J.T., Garnett G.P., et al. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 2006, 24(Suppl. 3):S251-S261.
81. Stanley M., Lowy D.R., Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006, 24(Suppl. 3):S106-S113. 10.1016/j.vaccine.2006.05.110.
82. Centers for Disease Control and Prevention Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR 2011, 60(50):1705-1708.
83. New Zealand Ministry of Health Human papillomavirus (HPV) immunisation programme 2010, [homepage on the Internet], Ministry of Health, Wellington (NZ), [updated 10 February, 2010; cited 2011 June 24]. Available from:. http://www.moh.govt.nz/moh.nsf/indexmh/immunisation-diseasesandvaccines-hpv-programme.
84. New Zealand Ministry of Health Immunisation schedule 2011, [homepage on the Internet], Ministry of Health, Wellington (NZ), [updated 19 May, 2011; cited 2011 June 24]. Available from:. http://www.moh.govt.nz/moh.nsf/indexmh/immunisation-schedule.
85. United Kingdom (UK) Department of Health Key vaccine information: HPV 2011, [homepage on the Internet], Department of Health, London (UK), [updated 26 May, 2011; cited 2011 June 24]. Available from:. http://www.dh.gov.uk/en/Publichealth/Immunisation/Keyvaccineinformation/DH_104010.
86. ® 2011, [homepage on the Internet], Department of Health and Aging, Canberra (Australia), [updated 28 November, 2006; cited 2011 June 24]. Available from:. http://www.health.gov.au/internet/main/publishing.nsf/Content/gardasil_hpv.htm.
87. IARC handbook of cancer prevention. Cervix cancer screening 2005, vol. 10. International Agency for Research on Cancer, Lyon (France).
88. Spitzer M. Cervical screening adjuncts: recent advances. Am J Obstet Gynecol 1998, 179(2):544-556.
89. Garnett G.P., Kim J.J., French K., Goldie S.J. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006, 24(Suppl. 3):S178-S186. 10.1016/j.vaccine.2006.05.116.
90. Manhart L.E., Koutsky L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002, 29(11):725-735.
91. Hogewoning C.J.A., Bleeker M.C.G., van den Brule A.J.C., Voorhorst F.J., Snijders P.J.F., Berkhof J., et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003, 107(5):811-816. 10.1002/ijc.11474.
92. Bleeker M.C.G., Hogewoning C.J.A., Voorhorst F.J., van den Brule A.J.C., Snijders P.J.F., Starink T.M., et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003, 107(5):804-810. 10.1002/ijc.11473.
93. Burd E.M. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003, 16(1):1-17.
94. Castellsagué X., Albero G., Cleries R., Bosch F.X. HPV and circumcision: a biased, inaccurate and misleading meta-analysis. J Infect 2007, 55(1):91-93. [author reply 3-6].
95. Van Howe R.S. Human papillomavirus and circumcision: a meta-analysis. J Infect 2007, 54(5):490-496.
96. Van Howe R.S. Sampling bias explains association between human papillomavirus and circumcision. J Infect Dis 2009, 200(5):832. [author reply 3-4].
97. Castellsagué X., Bosch F.X., Muñoz N., Meijer C.J.L.M., Shah K.V., de Sanjosé S., et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002, 346(15):1105-1112. 10.1056/NEJMoa011688.
98. Gray R.H., Serwadda D., Kong X., Makumbi F., Kigozi G., Gravitt P.E., et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis 2010, 201(10):1455-1462.
99. Hernandez B.Y., Shvetsov Y.B., Goodman M.T., Wilkens L.R., Thompson P., Zhu X., et al. Reduced clearance of penile human papillomavirus infection in uncircumcised men. J Infect Dis 2010, 201(9):1340-1343.
100. Lu B., Wu Y., Nielson C.M., Flores R., Abrahamsen M., Papenfuss M., et al. Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis 2009, 199(3):362-371.
101. Lajous M., Mueller N., Cruz-Valdez A., Aguilar L.V., Franceschi S., Hernandez-Avila M., et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 2005, 14(7):1710-1716.
102. Albero G., Castellsague X., Giuliano A.R., Bosch F.X. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis 2012, 39(2):104-113.
103. Auvert B., Sobngwi-Tambekou J., Cutler E., Nieuwoudt M., Lissouba P., Puren A., et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009, 199(1):14-19.
104. Tobian A.A.R., Serwadda D., Quinn T.C., Kigozi G., Gravitt P.E., Laeyendecker O., et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009, 360(13):1298-1309.
105. Tarnaud C., Lissouba P., Cutler E., Puren A., Taljaard D., Auvert B. Association of low-risk human papillomavirus infection with male circumcision in young men: results from a longitudinal study conducted in Orange Farm (South Africa). Infect Dis Obstet Gynecol 2011, 2011:567408.
106. Giuliano A.R., Lazcano E., Villa L.L., Flores R., Salmeron J., Lee J.-H., et al. Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Int J Cancer 2009, 124(6):1251-1257.
107. Dickson N.P., Ryding J., van Roode T., Paul C., Herbison P., Dillner J., et al. Male circumcision and serologically determined human papillomavirus infection in a birth cohort. Cancer Epidemiol Biomarkers Prev 2009, 18(1):177-183.
108. Vardas E., Giuliano A.R., Goldstone S., Palefsky J.M., Moreira E.D., Penny M.E., et al. External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J Infect Dis 2011, 203(1):58-65.
109. Vanbuskirk K., Winer R.L., Hughes J.P., Feng Q., Arima Y., Lee S.-K., et al. Circumcision and acquisition of human papillomavirus infection in young men. Sex Transm Dis 2011, 38(11):1074-1081.